Voyager Therapeutics, Inc. — Q1 2017 Form 10-Q
Reporting period: Three months ended March 31, 2017. Voyager is a clinical-stage gene-therapy company developing AAV treatments for severe neurological diseases. It has no approved products and generated no product-sale revenue; substantially all reported revenue comes from its Sanofi-Genzyme collaboration.
Financial results and liquidity
| Metric | Q1 2017 | Q1 2016 |
|---|---|---|
| Collaboration revenue | $1.464 million | $4.830 million |
| Research and development expense | $14.072 million | $8.732 million |
| General and administrative expense | $4.914 million | $3.565 million |
| Operating loss | $17.522 million | $7.467 million |
| Net loss | $16.648 million | $7.188 million |
| Net loss per share, basic and diluted | $0.65 | $0.29 |
| Net cash used in operating activities | $14.294 million | $9.487 million |
- Operating margin is not a useful indicator for this development-stage company: revenue is collaboration revenue, and operating expenses substantially exceed it.
- At March 31, cash and cash equivalents were $43.604 million; current marketable securities were $114.066 million, and non-current marketable securities were $2.000 million. The company cited $157.7 million of cash, cash equivalents and marketable debt securities as available liquidity and said it expected to fund its current plan into 2019.
- Total liabilities were $52.393 million, including $40.162 million of deferred revenue, deferred rent and other liabilities. The filing reports no borrowings or financial debt.
- Cash increased by $6.963 million during the quarter, primarily because $23.6 million of marketable securities matured; investing cash flow also included $2.945 million of property and equipment purchases. Financing cash inflow was $0.602 million, mainly from option exercises.
- Accumulated deficit was $106.663 million. The company expects continued significant expenses and operating losses and states it will need substantial additional funding for continuing operations.
Material changes versus the prior-year quarter
- Revenue declined $3.366 million. Voyager attributed this primarily to its 2016 decision to deprioritize VY-SMN101 for spinal muscular atrophy, reducing collaboration revenue by about $1.4 million per quarter, and a Q1 2017 extension of estimated service periods for two collaboration units, reducing quarterly revenue by a further $0.4 million prospectively.
- R&D expense rose $5.340 million, reflecting higher third-party research, preclinical and clinical work and lab-supply costs, increased headcount compensation, and higher facilities costs.
- G&A expense rose $1.349 million, primarily due to increased legal costs and headcount compensation.
- Net loss widened by $9.460 million. Operating cash use increased by $4.807 million.
Outlook, risks and other notable items
- Management plans continued investment in its AAV platform and development programs. It described ongoing Phase 1b work on VY-AADC01 for advanced Parkinson’s disease and potential advancement of VY-AADC02 into later-stage trials if the Phase 1b program is successful. The filing also identifies planned IND filings for VY-SOD101 in late 2017 or early 2018 and two other preclinical programs within 24 months as forward-looking objectives.
- Key uncertainties include clinical safety and efficacy, trial enrollment and completion, regulatory approval, manufacturing scale-up, delivery devices, intellectual-property protection, competition, collaboration-partner decisions, and access to additional financing. The company cautions that its cash-runway estimate depends on achieving its operating plan.
- Under the Genzyme collaboration, potential option, milestone and royalty payments depend on program progress and partner decisions; the filing describes up to $645 million in specified regulatory and commercial milestones across programs, plus potential tiered royalties. These are contingent, not assured, amounts.
- A $1.0 million development milestone received from a nonprofit funding arrangement was recorded as a long-term liability because repayment is considered probable; the agreement may require repayment of up to 2.6 times funding received upon successful development and commercialization.
- Operating lease commitments totaled $28.985 million through 2024. The filing reports no litigation, no off-balance-sheet arrangements, and effective disclosure controls as of March 31, 2017.
Important facts for investors to verify
- Whether clinical progress, timelines and planned IND filings remain on track, particularly for VY-AADC programs and VY-SOD101.
- Whether spending and collaboration revenue trends support the stated funding runway into 2019, and when additional capital may be required.
- The scope and financial effect of Genzyme option exercises, program priorities and any changes to collaboration revenue-recognition estimates.
- The terms and repayment exposure of the nonprofit funding arrangement, along with lease, licensing and other contingent commitments.
- The filing’s risk-factor discussion and the potential for dilution or unfavorable terms if Voyager raises additional capital.